Jazz Pharmaceuticals (JAZZ) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Jazz Pharmaceuticals published the results on November 2, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Jazz Pharmaceuticals reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Jazz Pharmaceuticals operates as a single segment. The rows above are the therapeutic-area and royalty lines from its total revenues table. Other product sales, $6.9 million in Q3 2025 and nil in Q3 2026, are left out.
• GAAP and non-GAAP adjusted results for Q3 2026 include $754.2 million of acquired in-process research and development expense for ABS-1230 (JZP6979) from the Actio acquisition, which Jazz does not exclude from its adjusted measures.

Source: Jazz Pharmaceuticals Q3 2026 results, November 2, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Jazz Pharmaceuticals splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Jazz Pharmaceuticals's Sleep revenue was $514 million in Q3 2026, up 10% from $467 million in Q3 2025, 41% of total revenue.
• Jazz Pharmaceuticals's Epilepsy (Epidiolex/Epidyolex) revenue was $295 million in Q3 2026, down 2% from $303 million in Q3 2025, 24% of total revenue.
• Jazz Pharmaceuticals's Oncology revenue was $387 million in Q3 2026, up 35% from $288 million in Q3 2025, 31% of total revenue.
• Jazz Pharmaceuticals's High-sodium oxybate AG royalty revenue revenue was $38.4 million in Q3 2026, down 27% from $52.9 million in Q3 2025, 3% of total revenue.
• Jazz Pharmaceuticals's Other royalty and contract revenues revenue was $8.1 million in Q3 2026, down 8% from $8.8 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Jazz Pharmaceuticals said:

“Raised 2026 total revenue guidance to a range of $4.775-$4.85 billion.”

“Jazz Pharmaceuticals has updated its full-year financial guidance, as shown in the table below, including raising its full-year 2026 revenue guidance, increasing its GAAP SG&A expense guidance to include restructuring expenses, and updating its effective tax rate guidance range to reflect the impact of the acquired IPR&D expense associated with the Actio acquisition.”

Source: Jazz Pharmaceuticals Q3 2026 release, Nov 2, 2026.

This is the company's own guidance as of Nov 2, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the JAZZ forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP figures, each as first reported in that quarter's release. Releases for Q4 2025 and Q3 2025 printed revenue in thousands ($1,197.9 million and $1,126.1 million), rounded here to one decimal in millions.

We do not hold a confirmed date for Jazz Pharmaceuticals's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 2, 2026

Jazz Pharmaceuticals' total revenues were $1,243.0 million in Q3 2026, up 10% from $1,126.1 million. Product sales, net were $1,196.5 million and royalties and contract revenues $46.5 million. By therapeutic area, Sleep brought in $514.0 million, Oncology $387.1 million and Epilepsy $295.4 million. Jazz said the increase came mainly from higher Xywav, Zepzelca and Ziihera sales and the inclusion of Modeyso, which the FDA approved in August 2025. (Jazz Pharmaceuticals Q3 2026 release, Nov 2, 2026)

Xywav is the largest single product, with net product sales of $482.8 million, up 12%. Jazz counted approximately 425 net patient adds in the quarter and approximately 17,550 active patients at its end, about 11,375 with narcolepsy and 6,175 with idiopathic hypersomnia. The 10-Q puts the rise down to volume growth of 10% and a higher selling price, offset by higher gross to net deductions. Xyrem fell to $31.2 million on a volume decline of 20%. (Jazz Pharmaceuticals Q3 2026 release, Nov 2, 2026; Jazz Pharmaceuticals Form 10-Q, Q3 2026, Nov 2, 2026)

In oncology, Zepzelca grew 32% to $104.4 million on uptake of the Zepzelca and atezolizumab combination in first-line maintenance extensive-stage small-cell lung cancer, partly offset by lower second-line use. Modeyso sales were $61.1 million against $11.0 million a year earlier, and about 725 patients have received it since its August 2025 launch. Ziihera was $20.6 million after its August 25, 2026 approval in first-line HER2-positive gastroesophageal adenocarcinoma. Epidiolex/Epidyolex fell 2% to $295.4 million, which Jazz attributed to lower U.S. gross-to-net deductions in Q3 2025 and lower inventory build in Q3 2026. (Jazz Pharmaceuticals Q3 2026 release, Nov 2, 2026)

Jazz Pharmaceuticals' sales are concentrated by country and by distributor. The U.S. accounted for $1,098.7 million of total revenues, Europe $95.7 million and all other markets $48.6 million. ESSDS, the central pharmacy that distributes Xywav and Xyrem in the U.S., accounted for 41% of total revenues, McKesson 12% and ASD 8%. High-sodium oxybate AG royalty revenue, from authorized generic versions of Xyrem, fell to $38.4 million from $52.9 million. (Jazz Pharmaceuticals Form 10-Q, Q3 2026, Nov 2, 2026; Jazz Pharmaceuticals Form 10-K, 2025, Feb 24, 2026)

Jazz Pharmaceuticals reported a GAAP net loss of $483.4 million, or $7.48 per diluted share, against net income of $251.4 million, or $4.08 per share, a year earlier. The loss came from $754.2 million of acquired in-process research and development expense, the value allocated to ABS-1230 (JZP6979) in the Actio acquisition. Jazz said this reduced results by $11.32 per share on a GAAP basis and $11.03 per share on a non-GAAP adjusted basis. Jazz does not exclude acquired IPR&D from its adjusted measures, so non-GAAP adjusted EPS was also a loss, of $3.88 per share. (Jazz Pharmaceuticals Q3 2026 release, Nov 2, 2026)

Jazz's non-GAAP adjusted figures exclude intangible asset amortization ($171.8 million in the quarter), share-based compensation ($73.8 million), restructuring and other costs ($34.2 million) and integration expenses, net of their tax effect. The 10-Q ties the restructuring cost to a proposed re-organization of Jazz's European operating model. GAAP SG&A fell to $407.9 million from $530.6 million because Q3 2025 carried $152 million of litigation settlements. (Jazz Pharmaceuticals Q3 2026 release, Nov 2, 2026; Jazz Pharmaceuticals Form 10-Q, Q3 2026, Nov 2, 2026)

Jazz recorded income tax expense of $24.5 million, against a benefit of $242.4 million a year earlier that included $206 million from recognizing deferred tax assets acquired with Chimerix. Diluted weighted-average shares were 64.7 million, against 61.6 million. In the quarter Jazz issued $1.25 billion of 1.875% exchangeable senior notes due 2032 and, alongside it, repurchased 0.9 million shares for $225.0 million, at $249.29 per share. In October 2026 its board approved a new repurchase program of up to $500 million. (Jazz Pharmaceuticals Q3 2026 release, Nov 2, 2026; Jazz Pharmaceuticals Form 10-Q, Q3 2026, Nov 2, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Jazz Pharmaceuticals publishes a full-year outlook table in its release and updates it each quarter. On November 2, 2026 it raised 2026 total revenue guidance to $4,775 million to $4,850 million, from $4,600 million to $4,750 million on August 3, 2026. It kept GAAP gross margin at 89% to 90% and raised GAAP SG&A expense guidance to $1,544 million to $1,597 million to include restructuring expenses. (Jazz Pharmaceuticals Q3 2026 release, Nov 2, 2026)

Jazz moved its GAAP effective tax rate guidance to 20% to 30%, from 0% to 10%, because of the acquired IPR&D expense from the Actio acquisition, and its non-GAAP adjusted rate to 19.5% to 21.5%. It expects 69 million to 70 million weighted-average diluted shares for the year. (Jazz Pharmaceuticals Q3 2026 release, Nov 2, 2026)

A consensus figure is the average of the models published by the analysts who cover Jazz Pharmaceuticals, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Jazz Pharmaceuticals's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning JAZZ is on is JAZZ a buy or a sell?, what analysts expect next is on the JAZZ forecast, and what the company does is on the Jazz Pharmaceuticals (JAZZ) stock page.

Every number on this page can be traced to a document Jazz Pharmaceuticals published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.